Vapotherm, Inc. (VAPO): Price and Financial Metrics
VAPO Price/Volume Stats
Current price | $1.04 | 52-week high | $9.36 |
Prev. close | $1.03 | 52-week low | $0.75 |
Day low | $1.00 | Volume | 700 |
Day high | $1.04 | Avg. volume | 8,730 |
50-day MA | $1.05 | Dividend yield | N/A |
200-day MA | $2.80 | Market Cap | 6.38M |
VAPO Stock Price Chart Interactive Chart >
VAPO POWR Grades
- Growth is the dimension where VAPO ranks best; there it ranks ahead of 96.75% of US stocks.
- VAPO's strongest trending metric is Sentiment; it's been moving down over the last 92 days.
- VAPO's current lowest rank is in the Sentiment metric (where it is better than 3.72% of US stocks).
VAPO Stock Summary
- Equity multiplier, or assets relative to shareholders' equity, comes in at -2.77 for VAPOTHERM INC; that's greater than it is for merely 4.74% of US stocks.
- In terms of volatility of its share price, VAPO is more volatile than 97.02% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VAPO comes in at -142.26% -- higher than that of merely 3.35% of stocks in our set.
- Stocks that are quantitatively similar to VAPO, based on their financial statements, market capitalization, and price volatility, are LAB, OWLT, KERN, BYND, and BMRA.
- VAPO's SEC filings can be seen here. And to visit VAPOTHERM INC's official web site, go to www.vapotherm.com.
VAPO Valuation Summary
- In comparison to the median Healthcare stock, VAPO's EV/EBIT ratio is 115.75% lower, now standing at -2.
- VAPO's EV/EBIT ratio has moved up 5.9 over the prior 61 months.
Below are key valuation metrics over time for VAPO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
VAPO | 2023-11-20 | 0.2 | -0.3 | -0.2 | -2 |
VAPO | 2023-11-17 | 0.2 | -0.3 | -0.2 | -2 |
VAPO | 2023-11-16 | 0.2 | -0.3 | -0.2 | -2 |
VAPO | 2023-11-15 | 0.2 | -0.3 | -0.2 | -2 |
VAPO | 2023-11-14 | 0.2 | -0.3 | -0.2 | -2 |
VAPO | 2023-11-13 | 0.2 | -0.3 | -0.2 | -2 |
VAPO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VAPO has a Quality Grade of F, ranking ahead of 3.49% of graded US stocks.
- VAPO's asset turnover comes in at 0.702 -- ranking 53rd of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows VAPO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.702 | 0.501 | -0.633 |
2021-06-30 | 0.636 | 0.505 | -0.633 |
2021-03-31 | 0.680 | 0.511 | -0.536 |
2020-12-31 | 0.688 | 0.501 | -0.623 |
2020-09-30 | 0.624 | 0.493 | -0.583 |
2020-06-30 | 0.572 | 0.480 | -0.610 |
Vapotherm, Inc. (VAPO) Company Bio
Vapotherm Inc. Vapotherm, Inc. is a global medical technology company. The Company is focused on the development and commercialization of its high velocity nasal insufflations (Hi-VNI) technology products that are used to treat patients suffering from respiratory distress. Its Hi-VNI technology delivers noninvasive ventilatory support by providing heated, humidified and oxygenated air at a high velocity to patients through a comfortable small-bore nasal interface. Its Precision Flow systems uses its Hi-VNI technology. It offers three versions of its Precision Flow systems: Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its Precision Flow versions are integrated systems that provide precise user control of temperature, air flow and percentage oxygen through a one-button interface.
Latest VAPO News From Around the Web
Below are the latest news stories about VAPOTHERM INC that investors may wish to consider to help them evaluate VAPO as an investment opportunity.
OTC Markets Group Welcomes Vapotherm, Inc. to OTCQXNEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for 12,000 U.S. and international securities, today announced Vapotherm, Inc. (OTCQX: VAPO), a global medical technology company specializing in the development and commercialization of its proprietary Vapotherm high-velocity therapy® products for patients of all ages experiencing respiratory distress, has qualified to trade on the OTCQX® Best Market. Vapotherm, Inc. voluntarily transf |
Vapotherm Announces Suspension of NYSE Listing Common Stock Expected to Begin Trading Promptly on OTCQXVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced it has received notice that the New York Stock Exchange ("NYSE") has determined to suspend trading of – and commence proceedings to delist – shares of the Company's common stock, effective immediately. This suspension was made because the Company fell below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30 trading day period of at l |
Vapotherm Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock Application Pending to Transfer Shares to OTCQXVapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company") today announced its intention to voluntarily delist its common stock from The New York Stock Exchange ("NYSE") and its filing of an application to have its common stock quoted on the OTCQX Marketplace ("OTCQX"). |
Vapotherm Educates over 8,000 Clinicians in Respiratory Care MonthVapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress is excited to announce the participation of over 8,000 clinicians in interactive, digital based, evidence based education focused on a variety of respiratory clinical topics. The education was free to clincians in celebration of Respiratory C |
Vapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call TranscriptVapotherm, Inc. (NYSE:VAPO) Q3 2023 Earnings Call Transcript November 8, 2023 Vapotherm, Inc. misses on earnings expectations. Reported EPS is $-2.38 EPS, expectations were $-2.2. Operator: Good afternoon, and welcome to Vapotherm’s Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] It is now my pleasure to turn today’s conference over to Dorota Mckay, Vapotherm’s […] |
VAPO Price Returns
1-mo | 1.96% |
3-mo | -60.75% |
6-mo | -68.96% |
1-year | -87.85% |
3-year | -99.54% |
5-year | -99.24% |
YTD | 4.00% |
2023 | -95.37% |
2022 | -86.96% |
2021 | -22.90% |
2020 | 120.89% |
2019 | -39.05% |
Loading social stream, please wait...